Miprosed (Midazolam)

Midazolam binds to the GABA‑A receptor as a positive allosteric modulator, increasing the frequency of chloride channel opening when GABA binds. This enhances neuronal inhibition, leading to sedation, anxiolysis, muscle relaxation, anticonvulsant activity, and amnesia.

The appropriate dose of Miprosed is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and intended use. Dosage regimens are individualized and should follow local prescribing guidelines and the prescriber’s judgment.

The safety of midazolam in pregnancy and lactation has not been definitively established. It is classified as pregnancy category unknown, and clinicians usually avoid its use unless the potential benefit justifies the potential risk to the fetus or infant. Breastfeeding mothers should discuss alternatives with their healthcare provider.

To request Miprosed, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. The team then replies with pricing, availability, shipping details (including any cold‑chain requirements) and required import documentation.

Midazolam has a rapid onset and relatively short duration compared with many other benzodiazepines, making it advantageous for procedural sedation and short‑term anxiolysis. Unlike longer‑acting agents such as diazepam, midazolam allows quicker recovery, but it still shares similar risks of respiratory depression and dependence.

Miprosed should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in areas with high humidity or direct sunlight.

Miprosed is formulated for oral administration. The tablet (or oral solution, if applicable) is swallowed whole with water. The exact route, timing and dosage are determined by the prescriber, who may adjust based on the intended clinical effect and patient response.

The most serious risks include respiratory depression, severe allergic reactions (anaphylaxis), and paradoxical reactions such as agitation or aggression. Patients with compromised breathing, severe sleep apnea, or those taking other central nervous system depressants require close monitoring.

Miprosed is contraindicated in patients with known hypersensitivity to midazolam or other benzodiazepines, those with severe obstructive sleep apnea, and individuals with acute narrow‑angle glaucoma. Caution is also advised for patients with significant hepatic impairment, the elderly, and those taking interacting CNS depressants.